Will Wegovy Work If Mounjaro Didn't Work For You?

Are Mounjaro and Wegovy different enough that one might work when the other didn't?

Yes, and the difference is pharmacological, not just cosmetic. Mounjaro (tirzepatide) activates two gut-hormone receptors: GIP and GLP-1. Wegovy (semaglutide 2.4mg) targets GLP-1 only. That dual action is why tirzepatide tends to produce greater average weight loss in trials, but it also means the two medicines interact with your biology in meaningfully different ways. If Mounjaro didn't deliver results, a prescriber would want to understand why before recommending Wegovy. Was the dose ever increased beyond the starting point? Were side effects so disruptive that the dose couldn't be titrated? Or did you reach the maintenance dose and simply not respond as expected? Each scenario points to a different clinical path. The average weight-loss percentages for semaglutide and tirzepatide are well-documented from large trials, but individual variation around those averages is substantial. A non-responder to one GLP-1-class medicine may respond differently to another, though this isn't guaranteed, and a prescriber needs the full picture. It's also worth noting that lifestyle factors (protein intake, activity, how consistently the medicine was taken) interact with how well either drug works. That context travels with you to any switch.

The mechanisms behind how Wegovy and Mounjaro work differ in ways that can matter clinically, particularly for people who experienced strong GIP-mediated effects or found the dual-agonist profile hard to tolerate.

What does the head-to-head evidence actually say?

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, compared tirzepatide directly against semaglutide 2.4mg in adults with obesity and no diabetes over 72 weeks. Tirzepatide produced greater average weight reduction. That result supports the general clinical picture, but it doesn't address your specific situation: it compared starting on one versus the other, not switching after a poor response.

For a fuller breakdown of the trial data, the Wegovy versus Mounjaro comparison covers the evidence in more depth, including what the SURMOUNT-5 results mean in practice. Both medicines are licensed by the MHRA and appraised by NICE (TA1026 for tirzepatide) and NICE (TA875 for semaglutide).

When might Wegovy be a reasonable next step, and when might it not be?

A prescriber reviewing a switch request would look at several things. If you stopped Mounjaro because of side effects (persistent nausea, gastrointestinal disruption) Wegovy shares a similar GI side-effect profile, since both slow gastric emptying. Switching may not resolve that issue, and in some people the GIP component of tirzepatide actually reduces nausea relative to a pure GLP-1 agonist. On the other hand, if Mounjaro produced poor results at a dose you tolerated well, trying a different mechanism is a rational clinical discussion. Some people keep their Wegovy pen in the fridge door alongside their Mounjaro had they not switched, the practical routine is nearly identical, once-weekly injection at a consistent time each week. The question of whether Wegovy works after Mounjaro is genuinely individual, which is why the prescriber's job is not to rubber-stamp a preference but to assess your treatment history, current weight, comorbidities, and any medicines that interact with either drug. Pages that explore what options exist when Mounjaro doesn't work outline the broader clinical conversation. The NHS medicines page for semaglutide also sets out what patients should discuss with their prescriber before starting.

How does a switch work in practice through a regulated pharmacy?

Transfer patients at a regulated private pharmacy (including anyone moving from one GLP-1 medicine to another) should expect clinical re-assessment, not automatic approval. At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber; a clinician, not software, reads your notes. Transfer patients are asked to provide evidence of their current treatment and dose history. That clinical record matters: if you were on 5mg Mounjaro and switched at six weeks, that's a different picture from someone who completed twelve months at 15mg without meaningful response. Questions about how Wegovy compares in practice often come down to exactly this kind of individual history. For context on what the medicines cost privately, a cost comparison between Wegovy and Mounjaro is worth reading before you decide, since price is part of the practical picture even if it shouldn't drive a clinical decision. To explore your options with our prescribers, start your free consultation, they'll review your history and help you work out which direction makes the most clinical sense for you.